Gastrointestinal hormones and weight management.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus.Current atherosclerosis reports · 2012
   Review
2. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.Cardiovascular diabetology · 2010
   Article
3. Advances in the treatment of prediabetes.Therapeutic advances in endocrinology and metabolism · 2010
   Article

Corrections and comments

• Comment on
  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as